Considering the individual differences of patients, such as the impact of PDL1 expression level, tumor mutation load, HRR mutation, expression of the FGFR2/3 genes and other factors on the therapeutic effect, more precise treatment plans can be formulated for patients with advanced or metastatic UC. This evidence concerns the gene FGFR2 and neoplasm.